Merus
Utrecht, NL · 209 employees on LinkedIn · 4 known investors
Find your way into Merus
1,007 people in our graph share verified history with the Merus team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows L. Andres Sirulnik · together at Dana-Farber Cancer Institute (overlapped)
×5knows the team · via PricewaterhouseCoopers LLP
×3knows the team · via University of Cambridge
knows the team · via Columbia University in the City of New York
×2knows the team · via University of Buenos Aires
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
Founders & leadership
TL
Ton LogtenberginFounder · CEO
MT
Mark ThrosbyinExecutive
HL
JC
John CrowleyinExecutive Vice President, Chief Financial Officer2016–2019He has served as a CFO at public life sciences companies and as a biotech board director, with experience in corporate strategy, capital raising, M&A transactions, and clinical-stage company operations.
LA
L. Andres SirulnikinExecutive Vice President and Chief Medical Officer2016–2020L. Andres Sirulnik trained as an academic researcher and practiced as a hematologist-oncologist for over a decade before joining Regeneron, where he led the hematology clinical development program. He is Executive Officer at Merus, which develops multispecific antibodies for oncology indications.
LB
Lex BakkerinEVP, Chief Development Officer & Head of Merus Utrecht2023–2024
Board
LM
Lionel M.S. CarnotBoard director
AM
Anand MehraBoard director
JP
GD
Gregory D. PerryBoard director
MT
WB
Wolfgang BertholdBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$150.8M disclosed across 3 rounds · 2017–2018
▶$15MraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ton LogtenbergExecutive Officer, Director
- Gregory D. PerryDirector
- Lex BakkerExecutive Officer
- Anand MehraDirector
- Mark ThrosbyExecutive Officer
- Russell GreigDirector
- Mark T. IwickiDirector
- John De KruifExecutive Officer
- John P. de KoningDirector
- Len KanavyDirector
- Hui LiuExecutive Officer
- L. Andres SirulnikExecutive Officer
- Peter SilvermanExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2018
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
▶$55.8MraisedFeb 2018 · 9 investors · BiotechnologyRule 506(b)
▶$55.8MraisedFeb 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ThrosbyExecutive Officer
- Gregory D. PerryDirector
- Mark T. IwickiDirector
- Lionel M.S. CarnotDirector
- Hui LiuExecutive Officer
- Wolfgang BertholdDirector
- Anand MehraDirector
- John CrowleyExecutive Officer
- John P. de KoningDirector
- L. Andres SirulnikExecutive Officer
- Ton LogtenbergExecutive Officer, Director
- Lex BakkerExecutive Officer
- Offering amount
- $55.8M
- Amount sold
- $55.8M
- First sale
- Feb 2018
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
▶$80MraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$80MraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anand MehraDirector
- Wolfgang BertholdDirector
- Shelley MargetsonExecutive Officer
- Mark T. IwickiDirector
- Gregory D. PerryDirector
- Jack B. NielsenDirector
- Lionel M.S. CarnotDirector
- Ton LogtenbergExecutive Officer
- John P. de KoningDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Jan 2017
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Globaldata23 shared keywordsGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
Agenus21 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Companies competing with Merus for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Merus do?
- Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
- Who founded Merus?
- Merus was founded by Ton Logtenberg.
- Who are Merus's investors?
- Merus's investors include Avoro Capital Advisors, Pfizer Venture Investments, RA Capital, Sofinnova Ventures.
- How much funding has Merus raised?
- Merus has disclosed $150.8M raised across 3 rounds.
- Where is Merus headquartered?
- Merus is headquartered in Utrecht, NL.